SKYSCRAPER-06...a study that randomized patients t
Post# of 148278
(Total Views: 508)
Posted On: 07/06/2024 7:48:02 PM
SKYSCRAPER-06...a study that randomized patients to receive either Tirogolumab and Roche's checkpoint inhibitor Tecentrig OR Merck & Co.'s KEYTRUDA and Chemo.
Roche found the survival rate favored the KEYTRUDA regimen at the First Interim Analysis.
The assessment of (PFS) generated a hazard rate of 1.27...Anything above 1. indicates the Control group performed better than the Investigational Treatment. ALL indications suggest KEYTRUDA patients are living LONGER. Roche at closing down 2%.
Roche found the survival rate favored the KEYTRUDA regimen at the First Interim Analysis.
The assessment of (PFS) generated a hazard rate of 1.27...Anything above 1. indicates the Control group performed better than the Investigational Treatment. ALL indications suggest KEYTRUDA patients are living LONGER. Roche at closing down 2%.
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼